Evidence map›Paper›PMID 37382440›Full record

ArticlemBio2023

Modulation of the functional interfaces between retroviral intasomes and the human nucleosome.

E Mauro, D Lapaillerie, C Tumiotto, C Charlier, F Martins, S F Sousa, M Métifiot, P Weigel, K Yamatsugu, M Kanai and 9 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 3 countries.

E MauroFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.
D LapaillerieFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.
C TumiottoFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.
C CharlierViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
F MartinsUCIBIO@REQUIMTE, BioSIM Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro , Porto, Portugal.
S F SousaUCIBIO@REQUIMTE, BioSIM Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro , Porto, Portugal.ORCID 0000-0002-6560-5284
M MétifiotFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.
P WeigelViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
K YamatsuguGraduate School of Pharmaceutical Sciences, The University of Tokyo , Tokyo, Japan.
M KanaiGraduate School of Pharmaceutical Sciences, The University of Tokyo , Tokyo, Japan.
H Munier-LehmannViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
C RichettaViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
M MaischViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
J DutrieuxViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
J BatisseViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
M RuffViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.
O DelelisViral DNA Integration and Chromatin Dynamics Network (DyNAVir) , Bordeaux, France.ORCID 0000-0001-9293-2558
P LesbatsFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.
V ParissiFundamental Microbiology and Pathogenicity Lab (MFP), UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed , Bordeaux, France.ORCID 0000-0003-1661-7841
Centre National de la Recherche Scientifique · FRTokyo University of Science · JPUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection by retroviruses as HIV-1 requires the stable integration of their genome into the host cells. This process needs the formation of integrase (IN)-viral DNA complexes, called intasomes, and their interaction with the target DNA wrapped around nucleosomes within cell chromatin. To provide new tools to analyze this association and select drugs, we applied the AlphaLISA technology to the complex formed between the prototype foamy virus (PFV) intasome and nucleosome reconstituted on 601 Widom sequence. This system allowed us to monitor the association between both partners and select small molecules that could modulate the intasome/nucleosome association. Using this approach, drugs acting either on the DNA topology within the nucleosome or on the IN/histone tail interactions have been selected. Within these compounds, doxorubicin and histone binders calixarenes were characterized using biochemical,

Indexed as

NucleosomesSpumavirusChromatinDNA, ViralHistonesHumansIntegrasesRetroviridaeVirus IntegrationChromatinDNA, ViralHistonesIntegrasesNucleosomesHIV-1host chromatineintegrationnucleosomeretrovirus

Identifiers

PMID37382440
PMCPMC10470491
OpenAlexW4382502707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.